Abstract
The challenges in everyday healthcare are very often related to the ability to provide the appropriate therapy to the patient. In this respect personalized treatment has became the focus of the modern medicine. The various forms of diseases require new diagnostic, therapeutic and prognostic markers that can serve as targets for personalized drug development. Biobank establishment has a great importance globally, as biobank has been identified as a key area in the drug development and in the discovery of new protein biomarkers. The fast progression of biobanks around the world is becoming an important resource for society where the patient benefit is in the focus. As part of a Swedish national cardiological research initiative, the development of a quantitative MRM assay is reported for the quantification of putative cardiovascular disease markers. The assay was utilized for the analysis of patient samples taken from the LUNDHEARTGENE biobank.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Addona TA, et al. A pipeline that integrate the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol. 2011;29:635–43.
Anderson NL. The role of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cell Proteomics. 2005;4:1441–4.
Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
Domanski D, et al. MRM-based multiplex quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics. 2012;12(8):1222–43.
Eiseman E, Bloom G, Brower J, et al., editors. Case studies of existing human tissue repositories: “best practices” for a biospecimen resource for the genomic and proteomic era. Santa Monica: RAND Corporation; 2003.
Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301–4.
Hewitt RE. Biobanking: the foundation of personalized medicine. Curr Opin Oncol. 2011;23(1):112–9.
Hüttenhain R, et al. Recent progress in selected reaction monitoring MS-driven plasma protein biomarker analysis. Curr Opin Chem Biol. 2009;13(5–6):518–25.
Jernberg T, et al. The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. 2010;96:1617–21.
Krastins B, et al. Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin Biochem. 2013;46(6):399–410.
Kuhn E, et al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem. 2009;55(6):1108–17.
LaBaer J. Improving international research with clinical specimens: 5 achievable objectives. J Proteome Res. 2012;11:5592–601.
Malm J, et al. Developments in biobanking workflow standardization providing sample integrity and stability. J Proteomics. 2013;95:38–45.
Marko-Varga G, Ogiwara A, Nishimura T, et al. Personalized medicine and proteomics: lessons from non-small cell lung cancer. J Proteome Res. 2007;6(8):2925–35.
Marko-Varga GA, Végvári Á, Fehniger TE. A protein shake-up. Public Serv Rev Eur Union. 2011;21:250–2.
Park A. Ten ideas changing the world right now: biobanks. Time. 2009;173(11):63.
Rezeli M, et al. Development of an MRM assay panel with application to biobank samples from patients with myocardial infarction. J Proteomics. 2013;87:16–25.
Simenon-Dubach D, Perren A. Better provenance for biobank samples. Nature. 2011;475(7357):454–5.
Vegvari A, Marko-Varga G. Clinical protein science and bioanalytical mass spectrometry with an emphasis on lung cancer. Chem Rev. 2010;110:3278–98.
Végvári Á, et al. Identification of a novel proteoform of prostate specific antigen (SNPL132I) in clinical samples by multiple reaction monitoring. Mol Cell Proteomics. 2013;12(10):2761–73.
Yabluchanskiy A, et al. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology (Bethesda). 2013;28(6):391–403.
Zolg JW, Langen H. How industry is approaching the search for new diagnostic maker and biomakers. Mol Cell Proteomics. 2004;3:345–54.
Acknowledgements
We would like to acknowledge The Kamprad Foundation, Thermo, the Swedish Foundation for Strategic Research, “TOTAL-AMI”, the Swedish Research Council, Vinnova, Knut and Alice Wallenberg Foundation, Crafoord Foundation, Carl Trygger Foundation and European Research Council Advanced Grant ERC-2011-294576.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Rezeli, M., Sjödin, K., Erlinge, D., Marko-Varga, G. (2014). Biomarker Discovery Utilizing Biobanking Archives and the Diagnostic Market. In: Marko-Varga, G. (eds) Genomics and Proteomics for Clinical Discovery and Development. Translational Bioinformatics, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9202-8_7
Download citation
DOI: https://doi.org/10.1007/978-94-017-9202-8_7
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-9201-1
Online ISBN: 978-94-017-9202-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)